In a patient with dry‑eye disease using Restasis (cyclosporine 0.05% ophthalmic emulsion) twice daily and Hycoscan artificial tears as needed, how much benefit can oral vitamin supplementation provide?

Oral Vitamin Supplementation in Dry Eye Disease

Oral vitamin supplementation provides minimal to modest benefit for dry eye disease and should be considered only as adjunctive therapy, not as primary treatment, in patients already using topical cyclosporine and artificial tears.

Evidence Quality and Limitations

The 2024 American Academy of Ophthalmology Dry Eye Preferred Practice Pattern 1 addresses oral supplements directly, noting that while omega-3 fatty acids were previously thought beneficial, a large-scale, masked, prospective study found no benefit of oral fatty acid supplements over 12 months compared with placebo in moderate to severe dry eye patients 1. The guideline rates this evidence as "I-, Moderate, Discretionary" - meaning it's discretionary and not strongly recommended.

For vitamins specifically, the evidence is even weaker. A 2026 systematic review 2 examining vitamins A, B1, B12, and D found that no studies were judged to be of high quality, with limitations including poor controls, inadequate power, very short follow-up, and variable dosing. Notably, no studies on vitamin C supplementation were identified 2.

What Limited Evidence Shows

Vitamin D

The most recent and highest quality evidence comes from a 2026 prospective comparative study 3 in vitamin D-deficient patients with dry eye. This study showed:

• Greater improvement in tear break-up time (TBUT) at 3 months when oral vitamin D (50,000 IU weekly for 8 weeks) was added to topical therapy versus topical therapy alone (adjusted mean difference 1.25 seconds, p<0.001)
• Improved Schirmer values (adjusted mean difference 1.45 mm, p<0.001)
• Reduced inflammatory cytokines (TNF-α, IL-1β, IL-4)

Critical caveat: This benefit was only demonstrated in patients with documented vitamin D deficiency (serum 25(OH)D <20 ng/mL), and partial attenuation occurred at 6 months after discontinuation 3.

Multivitamin Formulations

A 2022 study 4 of 42 patients with intractable dry eye showed that oral multivitamin supplementation improved TBUT and symptoms at 1 and 3 months. However, this was a small, uncontrolled study in patients refractory to conventional treatment 4.

Clinical Algorithm for Vitamin Supplementation

Step 1: Optimize topical therapy first

• Your patient is already on Restasis (cyclosporine 0.05%) BID 5 and artificial tears, which are evidence-based first-line treatments 1
• Consider adding other FDA-approved options before vitamins: lifitegrast, varenicline nasal spray, or perfluorohexyloctane drops 1

Step 2: Check vitamin D level

• If considering vitamin supplementation, measure serum 25(OH)D level
• Only if deficient (<20 ng/mL), consider vitamin D supplementation (50,000 IU weekly for 8 weeks) 3

Step 3: Set realistic expectations

• Any benefit from vitamins is adjunctive only - expect modest improvements in tear film parameters, not dramatic symptom resolution
• The systematic review concluded available evidence is "limited" 2

Common Pitfalls to Avoid

1. Don't recommend vitamins as primary therapy - they are not guideline-recommended first-line treatment 1
2. Don't supplement without checking vitamin D status - the only quality evidence is in deficient patients 3
3. Don't use omega-3 fatty acids - large-scale evidence shows no benefit 1
4. Don't expect sustained benefit - effects may attenuate over time 3

Bottom Line

In your patient already using Restasis and artificial tears, oral vitamin supplementation offers minimal additional benefit unless vitamin D deficiency is documented. Focus instead on optimizing topical therapy, considering short-term low-dose corticosteroids for inflammation 1, or adding newer FDA-approved agents like lifitegrast or varenicline nasal spray 1 before turning to vitamins.